Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.
Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.
The company will make and sell a Manchester-developed diagnostic reagent technology through an agreement that includes a research collaboration.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.